Synergistic induction of apoptosis by acyclic retinoid and interferon-β in human hepatocellular carcinoma cells

Hepatology

Volumn 36, Issue 5 5 II, 2002, Pages 1115-1124

  Obora, Akihiro ^a   Shiratori, Yoshimune ^a   Okuno, Masataka ^a   Adachi, Seiji ^a   Takano, Yukihiko ^a   Matsushima Nishiwaki, Rie ^a   Yasuda, Ichiro ^a   Yamada, Yasuhiro ^a   Akita, Kuniharu ^a   Sano, Tetsuro ^a   Shimada, Jun ^b   Kojima, Soichi ^b   Okano, Yukio ^a   Friedman, Scott L ^c   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b RIKEN   (Japan)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; DNA FRAGMENT; INTERFERON RECEPTOR; RETINOIC ACID; RETINOID; STAT1 PROTEIN;

APOPTOSIS; ARTICLE; BINDING KINETICS; CANCER CELL CULTURE; CELL GROWTH; CHEMOPROPHYLAXIS; CHROMATIN CONDENSATION; CONTROLLED STUDY; DNA BINDING; ENZYME INDUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 0036829479     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36369     Document Type: Article

References (44)

1. Shiratori Y, Yoshida H, Omata M. Different clinicopathological features of hepatocellular carcinoma in relation to causative agents. J Gastroenterol 2001;36:73-78.
2. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
3. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997;25:87-92.
4. Koda M, Murawaki Y, Misuda A, Ohyama K, Horie Y, Suou T, Kawasaki H, et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer 2000;88:529-537.
5. Chen Y-J, Yeh S-H, Chen J-T, Wu C-C, Hsu M-T, Tsai S-F, Chen P-J, et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000;119:431-440.
6. Okuno M, Kojima S, Moriwaki H. Chemoprevention of hepatocellular carcinoma: Concept progress and perspectives. J Gastroenterol Hepatol 2001;16:1329-1335.
7. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996;334:1561-1567.
8. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999;340:1046-1047.
9. International Interferon-alfa HCC Study Group. Effect of interferon-alfa on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. Lancet 1998;351:1535-1539.
10. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-1402.
11. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174-181.
12. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, et al. Interferon β prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: A prospective randomized study of hepatitis C-related liver cancer. Hepatology 2000;32:228-232.
13. Muto Y, Moriwaki H. Antitumor activities of vitamin A and its derivatives. J Natl Cancer Inst 1984;73:1389-1393.
14. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nature Rev Cancer 2001;1:181-193.
15. Yasuda I, Shiratori Y, Adachi S, Obora A, Takemura M, Okuno M, Shidoji Y, et al. Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J Hepatol 2002;660-671.
16. Moriwaki H, Yasuda I, Shiratori Y, Uematsu T, Okuno M, Muto Y. Deletion of serum lectin-reactive α-fetoprotein by acyclic retinoid: A potent biomarker in the chemoprevention of second primary hepatoma. Clin Cancer Res 1997;3:727-731.
17. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schants SP, Ota DM, Schusterman MA, et al. 13-cis-retinoic acid and interferon alpha-2a: Effective combination therapy for advanced squamous cell carcinoma on the skin. J Natl Cancer Inst 1992;84:235-241.
18. Lindner DJ, Borden EC, Kalvakolanu DV. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res 1997;3:931-937.
19. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against head and neck squamous cell carcinoma. Cancer Res 1998;58:5551-5558.
20. Gutterman JU. Cytokine therapeutics: Lessons from interferon alpha. Proc Natl Acad Sci U S A 1994;91:1198-1205.
21. Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, Akiba J, Kojiro M. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999;29:1708-1717.
22. Murphy D, Detjen KM, Welzel M, Wiedenmann B, Rosewicz S. Interferon alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 2001;33:346-356.
23. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, Corbett TJ, et al. Recombinant interferon alpha in inoperable hepatocellular carcinoma: A randomized control trial. Hepatology 1993;17:389-394.
24. The Gastrointestinal Tumor Study Group. A prospective trial of recombinant human interferon alpha 2b in previously untreated patients with hepatocellular carcinoma. Cancer 1990;66:135-139.
25. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-58.
26. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
27. Ihle JN. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv Immunol 2001;60:1-35.
28. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-264.
29. Kolla V, Lindner DJ, Weihua X, Borden EC, Kalvakolanu DV. Modulation of interferon (IFN)-inducible gene expression by retinoic acid: Upregulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem 1996;271:10508-10514.
30. Weihua X, Kolla V, Kalvakolanu DV. Modulation of interferon action by retinoids: Induction of murine STAT1 gene expression by retinoic acid. J Biol Chem 1997;272:9742-9748.
31. Chin YE, Kitagawa M, Kuida K, Flavell PA, Fu X-Y. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 1997;17:5328-5337.
32. Castelli JC, Hassel BA, Maran A, Paranjape J, Hewitt JA, Li XL, Hsu YT, et al. The role of 2′-5′ oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ 1998;5:313-320.
33. Matsushima-Nishiwaki R, Okuno M, Adachi S, Sano T, Akita K, Moriwaki H, Friedman SL, et al. Phosphorylation of retinoid X receptor α at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res 2001;61:7675-7682.
34. Okuno M, Akita K, Moriwaki H, Kawada N, Ikeda K, Kaneda K, Suzuki Y, et al at. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-β. Gastroenterology 2001;120:1784-1800.
35. Shimada J, Suzuki Y, Kim S-J, Wang P-C, Matsumura M, Kojima S. Transactivation via RAR/RXR-Sp1 interaction: Characterization of binding between Sp1 and GC box motif. Mol Endocrinol 2001;15:1677-1692.
36. Tubura E. The phase I and early phase II studies of human lymphoblast interferon (MOR-22) in the treatment of malignant tumors. J Jpn Soc Cancer Ther 1986;21:1049-1058.
37. Qin XQ, Runkel L, Deck C, DeDios C, Barsoum J. Interferon-β induces S phase accumulation selectivity in human transformed cell. J Interferon Cytokine Res 1997;17:355-367.
38. Balkwill F, Taylor-Papadimitriou J. Interferon affects both G1 and S+G2 in cells stimulated from quiescence to growth. Nature 1978;274:798-800.
39. Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S, Grander D. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ 1997;8:343-352.
40. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 1990;50:3473-3486.
41. WAF1/CIP1 mediated by STAT1. Science 1996;272:719-722.
42. (WAF1/CIP1) gene by retinoic acid receptor: Correlation with retinoid induction of U937 cell differentiation. J Biol Chem 1996;271:31723-31728.
43. Melen K, Keskinen P, Lehtonen A, Julkunen I. Interferon-induced gene expression and signaling in human hepatoma cell lines. J Hepatol 2000;33:764-772.
44. Adachi S, Okuno M, Matsushima-Nishiwaki R, Takano Y, Kojima S, Friedman SL, Moriwaki H, et al. Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. Hepatology 2002;35:332-340.